Video
Author(s):
D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.
D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the phase II ALTA trial, which is exploring brigatinib (Alunbrig) in crizotinib (Xalkori)-refractory patients with ALK-positive non—small cell lung cancer, during an interview at the IASLC 18th World Conference on Lung Cancer in Yokohama, Japan.
There is now an embarrassment of riches regarding ALK inhibitors, one of which is brigatinib, Camidge explains. In the ALTA trial, 2 doses of brigatinib were explored: 90 mg and 180 mg, the latter of which was given after 7 days of the 90-mg dose of brigatinib. The median progression-free survival (PFS) with the 90-mg dose is about 9 months; however, the 180-mg dose with the median PFS is now over 16 months, Camidge says.
Now, Camidge questions whether these findings will translate into better efficacy when used in the first-line setting.